OutSee conjures Cambridge-Finland AI alliance to fight dementia
OutSee’s proprietary AI technology, Nomaly, provides a novel approach to analysing genetic cohorts and to genomics-led discovery of causal mechanisms. Now it seeks to examine predictions from its hypothesis-free, reverse genetics approach – Nomaly – for improved understanding of dementia and for novel target identification.
The collaboration includes access to pseudonymised genotype and selected phenotype data of Finnish biobank donors with dementia. Data access is enabled through FINBB’s Fingenious® service, a first-in-class digital gateway to Finnish public biobanks and biomedical research.
Julian Gough, CEO of OutSee, says: “Nomaly’s predictive genetic analysis can unlock further biological insights beyond that of current associative methods alone.
“We are delighted to start this collaboration with FINBB to discover new targets and biomarkers in dementia. We are looking forward to applying our proven technology on high quality pseudonymised data and are grateful to all the Finnish biobank donors for sharing their data to improve human health.”
Marco Hautalahti, CEO of FINBB, added: “Public-private partnerships with R & D-focused innovative companies like OutSee have the potential to develop innovations and benefit patients suffering from devastating diseases like dementia. We are very excited about our new and meaningful collaboration and making things happen in practice.”
The overarching aim of the collaboration is to identify new targets and biomarkers related to dementia, unlocking new-value and insights from existing population-based data.
OutSee has applied Nomaly to UK Biobank and Genomics England data and will validate and expand the results using the dataset from Helsinki biobank. Examination of predictions will involve statistical tests and validation of promising findings for drug development.
FINBB is a biobank cooperative owned by Finland’s five wellbeing services counties, HUS, six largest universities in Finland, and the Finnish Institute for Health and Welfare.
All public Finnish biobanks are members of FINBB which coordinates the operations of the biobank network in Finland and aims to create an internationally advanced biobank infrastructure.
The organisation plays a significant role in the implementation and internationalisation of the Finnish National Health Sector Growth Strategy. FINBB’s Fingenious® service is the digital gateway to Finnish biobanks and biomedical research.
OutSee is a Cambridge, UK biotech company founded in 2024 to apply its predictive technology, Nomaly, in drug target discovery. Nomaly represents a step change from current associative methods by using novel AI predictive methodologies invented by founder Julian Gough.
The company has already applied Nomaly to over 500,000 human genomes to identify novel disease targets and biomarkers. OutSee is backed by the leading deep science VC investor Ahren.
